uric acid has been researched along with Hypertriglyceridemia in 69 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 9.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| "To describe the effect of Coenzyme Q10 (CoQ10) (added to either a fibrate, or polyunsaturated fatty acids (PUFA) or association of both) in patients affected by massive hypertriglyceridemia (MHTG) resistant to fibrates and PUFA." | 9.11 | Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. ( Cicero, AF; Derosa, G; Gaddi, A; Laghi, L; Miconi, A; Nascetti, S, 2005) |
| "These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X." | 9.09 | Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. ( Blane, G; Idzior-Walus, B; Kawalec, E; Rostworowski, W; Sieradzki, J; Wójcik, J; Zarnecki, A; Zdzienicka, A, 2000) |
| "Accumulating evidence suggests that elevated serum uric acid (SUA) may be a risk factor for hypertriglyceridemia (HTG)." | 8.31 | The association between serum uric acid and hypertriglyceridemia: evidence from the national health and nutrition examination survey (2007-2018). ( Li, F; Mo, CY; Tan, MY; Zhao, Q, 2023) |
| "This study investigated the association between serum uric acid (sUA) and stroke risk in men with hypertriglyceridemia." | 7.91 | Is serum uric acid a predictive factor for stroke in men with hypertriglyceridemia? ( Hsu, CY; Lai, YJ, 2019) |
| "Uric acid-lowering therapy benefits hyperlipidemia in gouty patients." | 7.91 | Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. ( Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP, 2019) |
| "Hypertriglyceridemia is one of lipid metabolism abnormalities; however, it is still debatable whether serum uric acid is a cause or a consequence of hypertriglyceridemia." | 7.85 | Serum Uric Acid Levels and Risk of Incident Hypertriglyceridemia: A Longitudinal Population-based Epidemiological Study. ( Chen, C; Chen, Q; Mao, Y; Ren, P; Yang, T; Zheng, R, 2017) |
| "Several studies have demonstrated a relationship between increased serum uric acid (SUA) concentrations and the prevalence of metabolic syndrome (MetS) in the oriental population." | 7.81 | Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study. ( Babio, N; Basora, J; Becerra-Tomás, N; Corella, D; Estruch, R; Fitó, M; Martínez-González, MA; Ortega-Calvo, M; Recondo, J; Ros, E; Salas-Salvadó, J; Serra-Majem, L; Wärnberg, J, 2015) |
| "The relationship between uric acid metabolism and lipid levels was analyzed in 148 male subjects with primary gout." | 7.67 | Relationship between hypertriglyceridemia and uric acid production in primary gout. ( Jiao, S; Kubo, M; Matsubara, K; Matsuzawa, Y; Takama, T; Tarui, S, 1989) |
| "Hyperuricemia is associated with metabolic syndrome (MetS), but the association is often confounded by the shared background of obesity." | 5.46 | Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia. ( Du, T; Li, M; Lin, X; Lu, H; Yu, X; Zhang, S, 2017) |
| "Hyperuricemia was defined as SUA ≥70 mg/L in men and ≥60 mg/L in women." | 5.38 | Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. ( Gonçalves, JP; Lopes, C; Oliveira, A; Santos, AC; Severo, M, 2012) |
| "Uric acid (UA) has been frequently reported to be associated with MetS in the general population." | 5.38 | The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder. ( Chen, CH; Chen, PY; Chiu, CC; Huang, MC; Lu, ML; Tsai, CJ, 2012) |
| "Moreover, hyperuricemia is significantly correlated with hypertriglyceridemia, hypertension, and visceral obesity." | 5.35 | Serum uric acid levels and risk of metabolic syndrome in healthy adults. ( Bandarian, F; Ebrahimpour, P; Fakhrzadeh, H; Heshmat, R; Larijani, B, 2008) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 5.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| "Metabolic syndrome was diagnosed using the WHO criteria." | 5.34 | Serum uric acid level as an independent component of the metabolic syndrome in type 2 diabetic blacks. ( Akande, AA; Akinyinka, OA; Jimoh, AK; Olarinoye, GO, 2007) |
| "To describe the effect of Coenzyme Q10 (CoQ10) (added to either a fibrate, or polyunsaturated fatty acids (PUFA) or association of both) in patients affected by massive hypertriglyceridemia (MHTG) resistant to fibrates and PUFA." | 5.11 | Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. ( Cicero, AF; Derosa, G; Gaddi, A; Laghi, L; Miconi, A; Nascetti, S, 2005) |
| "These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X." | 5.09 | Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. ( Blane, G; Idzior-Walus, B; Kawalec, E; Rostworowski, W; Sieradzki, J; Wójcik, J; Zarnecki, A; Zdzienicka, A, 2000) |
| " The link between increased fructose consumption and increases in uric acid also has been confirmed as a potential risk factor for metabolic syndrome, and insulin resistance/hyperinsulinemia may be causally related to the development of hypertension." | 4.91 | Health implications of high-fructose intake and current research. ( de Lima, WG; Dornas, WC; Pedrosa, ML; Silva, ME, 2015) |
| " Apart from the diagnostic criteria, MetS has also been associated with other risk factors including waist to hip ratio, high density lipoprotein dysfunction, small dense low density lipoprotein, postprandial hypertriglyceridaemia, lipoprotein (a), uric acid, liver function tests, prothrombotic factors, cytokines, adipokines, vitamin D, arterial stiffness, renal dysfunction, nephrolithiasis, polycystic ovary syndrome, obstructive sleep apnea." | 4.90 | Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. ( Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP, 2014) |
| "Accumulating evidence suggests that elevated serum uric acid (SUA) may be a risk factor for hypertriglyceridemia (HTG)." | 4.31 | The association between serum uric acid and hypertriglyceridemia: evidence from the national health and nutrition examination survey (2007-2018). ( Li, F; Mo, CY; Tan, MY; Zhao, Q, 2023) |
| " 113 patients fulfilled the criteria for central obesity with the mean uric acid level of 8." | 4.12 | A Clinical Profile of Patients with Hyperuricemia and the Relationship between Hyperuricemia and Metabolic Syndrome: A Cross-sectional Study at a Tertiary Hospital in the Indian Population. ( Ingawale, S; Raghorte, N; Rajadhyaksha, A; Sarate, N, 2022) |
| "This study investigated the association between serum uric acid (sUA) and stroke risk in men with hypertriglyceridemia." | 3.91 | Is serum uric acid a predictive factor for stroke in men with hypertriglyceridemia? ( Hsu, CY; Lai, YJ, 2019) |
| "Uric acid-lowering therapy benefits hyperlipidemia in gouty patients." | 3.91 | Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. ( Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP, 2019) |
| "Hypertriglyceridemia is one of lipid metabolism abnormalities; however, it is still debatable whether serum uric acid is a cause or a consequence of hypertriglyceridemia." | 3.85 | Serum Uric Acid Levels and Risk of Incident Hypertriglyceridemia: A Longitudinal Population-based Epidemiological Study. ( Chen, C; Chen, Q; Mao, Y; Ren, P; Yang, T; Zheng, R, 2017) |
| "Several studies have demonstrated a relationship between increased serum uric acid (SUA) concentrations and the prevalence of metabolic syndrome (MetS) in the oriental population." | 3.81 | Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study. ( Babio, N; Basora, J; Becerra-Tomás, N; Corella, D; Estruch, R; Fitó, M; Martínez-González, MA; Ortega-Calvo, M; Recondo, J; Ros, E; Salas-Salvadó, J; Serra-Majem, L; Wärnberg, J, 2015) |
| " With the reduction of serum potassium quartiles, participants were tended to have higher level of triglycerides and uric acid, lower level of high-density lipoprotein cholesterol (HDL-C), larger waist circumference and more severe insulin resistance." | 3.80 | Serum potassium level is associated with metabolic syndrome: a population-based study. ( Bi, Y; Li, M; Liu, J; Lu, J; Ning, G; Su, T; Sun, K; Xu, B; Xu, M, 2014) |
| "The increasing of uric acid level (hyperuricosuria) is regularly detected in blood during the examination of patient with such cardiovascular diseases as arterial hypertension, atherosclerosis, diabetes mellitus, metabolic syndrome and obesity." | 3.78 | [The hyperuricosuria in patients with high content of triglycerides: the combination of genetic and environmental factors and tactics of treatment]. ( Ameliushkina, VA; Iarovaia, EB; Kotkina, TI; Malusheva, PP; Rozhkova, TA; Titov, VN, 2012) |
| " Potassium supplementation improves their insulin resistance and hypertension, whereas allopurinol reduces serum levels of uric acid and ameliorates hypertension, hypertriglyceridemia, hyperglycemia, and insulin resistance." | 3.74 | Thiazide diuretics exacerbate fructose-induced metabolic syndrome. ( Johnson, RJ; Mu, W; Nakagawa, T; Reungjui, S; Roncal, CA; Sirivongs, D; Srinivas, TR, 2007) |
| "The prevalence of hypertriglyceridemia significantly increased with increased level of serum uric acid among both the men and women." | 3.73 | [Association between serum uric acid and triglyceride in a Chinese community]. ( Liu, J; Liu, S; Qin, LP; Wang, W; Wang, WH; Wu, GX; Zeng, ZC; Zhao, D; Zhao, LJ, 2005) |
| " The diabetic dams presented hyperglycemia, hyperlipemia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, decreased reduced glutathione (GSH), hepatic glycogen and superoxide dismutase (SOD) determinations." | 3.71 | Oxidative stress and diabetes in pregnant rats. ( Cunha Rudge, MV; Damasceno, DC; de Mattos Paranhos Calderon, I; Volpato, GT, 2002) |
| " The high prevalence and severity of metabolic disturbances associated with the insulin resistance syndrome (hyperglycaemia, hyperinsulinaemia, decreased HDL cholesterol, hypertriglyceridaemia, elevated fibrinogen levels and hyperuricaemia) before gastroplasty were significantly decreased after weight loss." | 3.70 | Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. ( Desaive, C; Dewe, W; Gielen, JE; Lefebvre, PJ; Luyckx, FH; Scheen, AJ, 1998) |
| "We carried out a study of 43 male asymptomatic subjects with high levels of uric acid but showing no signs of arterial hypertension, obesity or alcohol abuse." | 3.68 | Hyperuricemia-hyperlipemia association in the absence of obesity and alcohol abuse. ( Añon Barbudo, J; Collantes Estevez, E; Pineda Priego, M; Sanchez Guijo, P, 1990) |
| "The relationship between uric acid metabolism and lipid levels was analyzed in 148 male subjects with primary gout." | 3.67 | Relationship between hypertriglyceridemia and uric acid production in primary gout. ( Jiao, S; Kubo, M; Matsubara, K; Matsuzawa, Y; Takama, T; Tarui, S, 1989) |
| "Fenofibrate is a marketed fibric acid derivative for lipid-lowering in patients with lipid disorders." | 2.72 | Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis. ( Chen, Y; Dong, Z; Ji, X; Li, C; Li, R; Lu, J; Zhang, J; Zhao, Y, 2021) |
| "Hyperuricemia were defined as serum uric acid levels ≥7." | 1.56 | Sex-specific association of hyperuricemia with cardiometabolic abnormalities in a military cohort: The CHIEF study. ( Hoshide, S; Kwon, Y; Lee, JT; Lin, CS; Lin, GM; Lin, YK; Lin, YP; Su, FY; Tsai, KZ; Wu, TJ, 2020) |
| "The overall prevalence of NAFLD was 28." | 1.56 | Associations between obesity and metabolic health with nonalcoholic fatty liver disease in elderly Chinese. ( Chen, G; Chen, XH; He, H; Kuang, Y; Lin, BY; Wu, LM; Zheng, SS, 2020) |
| " KEY MESSAGES The natural cubic spline model showed a positive linear dose-response relationship between serum uric acid levels and hypertriglyceridaemia." | 1.56 | Serum uric acid and risk of incident hypercholesterolaemia and hypertriglyceridaemia in middle-aged and older Chinese: a 4-year prospective cohort study. ( Jia, C; Li, Y; Tian, L; Zheng, H, 2020) |
| "Hyperuricemia is associated with metabolic syndrome (MetS), but the association is often confounded by the shared background of obesity." | 1.46 | Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia. ( Du, T; Li, M; Lin, X; Lu, H; Yu, X; Zhang, S, 2017) |
| "Hyperuricemia is characterized by inhibited nitric oxide system and enhanced synthesis of reactive oxygen species." | 1.42 | Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI. ( Barbieri, L; Cassetti, E; De Luca, G; Marino, P; Schaffer, A; Suryapranata, H; Verdoia, M, 2015) |
| " The high and low dosage of chicory inulin also decreased serum UA levels on days 7, 14, and 28." | 1.40 | Effects of chicory inulin on serum metabolites of uric acid, lipids, glucose, and abdominal fat deposition in quails induced by purine-rich diets. ( Jin, R; Lin, Z; Liu, X; Zhang, B; Zhu, W, 2014) |
| "Hyperuricemia was defined as SUA ≥70 mg/L in men and ≥60 mg/L in women." | 1.38 | Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. ( Gonçalves, JP; Lopes, C; Oliveira, A; Santos, AC; Severo, M, 2012) |
| "Uric acid (UA) has been frequently reported to be associated with MetS in the general population." | 1.38 | The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder. ( Chen, CH; Chen, PY; Chiu, CC; Huang, MC; Lu, ML; Tsai, CJ, 2012) |
| "Hyperuricemia was defined as ≥ 6." | 1.38 | Gender distribution of serum uric acid and cardiovascular risk factors: population based study. ( Baldo, MP; Capingana, P; Dantas, EM; Magalhães, P; Mill, JG; Molina, Mdel C; Morelato, RL; Rodrigues, SL; Salaroli, LB, 2012) |
| "Moreover, hyperuricemia is significantly correlated with hypertriglyceridemia, hypertension, and visceral obesity." | 1.35 | Serum uric acid levels and risk of metabolic syndrome in healthy adults. ( Bandarian, F; Ebrahimpour, P; Fakhrzadeh, H; Heshmat, R; Larijani, B, 2008) |
| "Thus, cancer cells can no longer divide and cancer activity is inhibited." | 1.34 | Anatomical relationship between traditional acupuncture point ST 36 and Omura's ST 36 (True ST 36) with their therapeutic effects: 1) inhibition of cancer cell division by markedly lowering cancer cell telomere while increasing normal cell telomere, 2) im ( Chen, Y; Duvvi, H; Lu, DP; Ohki, M; Omura, Y; Shimotsura, Y, 2007) |
| "Metabolic syndrome was diagnosed using the WHO criteria." | 1.34 | Serum uric acid level as an independent component of the metabolic syndrome in type 2 diabetic blacks. ( Akande, AA; Akinyinka, OA; Jimoh, AK; Olarinoye, GO, 2007) |
| "Hyperuricemia and gout have shown an increase worldwide." | 1.33 | The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. ( Dong, Y; Gao, W; Nan, H; Qian, R; Qiao, Q; Tang, B; Tuomilehto, J, 2006) |
| "Insulin resistance is a risk factors for non-alcoholic fatty liver disease (NAFLD) and for gallstone disease (GD)." | 1.33 | Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. ( Bertolotti, M; Carulli, L; Carulli, N; D'Amico, R; Ganazzi, D; Lombardini, S; Lonardo, A; Loria, P; Rudilosso, A; Verrone, A, 2005) |
| "In idiopathic uric acid nephrolithiasis, urinary pH and fractional excretion of urate are significantly lower than in control subjects, suggestive of defects in urinary acidification and urate excretion." | 1.31 | Biochemical profile of idiopathic uric acid nephrolithiasis. ( Frawley, WH; Pak, CY; Peterson, RD; Poindexter, JR; Sakhaee, K, 2001) |
| "The prognosis of IgA nephropathy (IgAN) is variable and about 10-20% of patients progress to end-stage renal disease (ESRD) in 10 years." | 1.31 | Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. ( Mustonen, J; Pasternack, A; Syrjänen, J, 2000) |
| "Patients with NIDDM had 11% increase of high density lipoprotein-cholesterol (HDL-C) level at the end of the first, and 18% increase at the end of the second month, while patients with primary hyperlipoproteinaemia did not change significantly." | 1.30 | Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia. ( Balogh, Z; Boda, J; Kárpáti, L; Kovács, P; Leövey, A; Paragh, G; Szabó, J, 1997) |
| "Insulin resistance was estimated by homeostasis model assessment (HOMA(IR)), preliminarily validated against a euglycemic-hyperinsulinemic clamp in 85 subjects." | 1.30 | Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. ( Alberiche, M; Bonadonna, RC; Bonora, E; Egger, G; Kiechl, S; Muggeo, M; Oberhollenzer, F; Targher, G; Willeit, J, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.90) | 18.7374 |
| 1990's | 14 (20.29) | 18.2507 |
| 2000's | 17 (24.64) | 29.6817 |
| 2010's | 26 (37.68) | 24.3611 |
| 2020's | 10 (14.49) | 2.80 |
| Authors | Studies |
|---|---|
| Rajadhyaksha, A | 1 |
| Sarate, N | 1 |
| Raghorte, N | 1 |
| Ingawale, S | 1 |
| Teramura, S | 1 |
| Yamagishi, K | 1 |
| Umesawa, M | 1 |
| Hayama-Terada, M | 1 |
| Muraki, I | 1 |
| Maruyama, K | 1 |
| Tanaka, M | 1 |
| Kishida, R | 1 |
| Kihara, T | 1 |
| Takada, M | 1 |
| Ohira, T | 1 |
| Imano, H | 1 |
| Shimizu, Y | 1 |
| Sankai, T | 1 |
| Okada, T | 1 |
| Kitamura, A | 1 |
| Kiyama, M | 1 |
| Iso, H | 1 |
| Tan, MY | 1 |
| Mo, CY | 1 |
| Li, F | 1 |
| Zhao, Q | 1 |
| Kim, YK | 1 |
| Yang, YM | 1 |
| Lin, YK | 1 |
| Lin, YP | 1 |
| Lee, JT | 1 |
| Lin, CS | 1 |
| Wu, TJ | 1 |
| Tsai, KZ | 1 |
| Su, FY | 1 |
| Kwon, Y | 1 |
| Hoshide, S | 1 |
| Lin, GM | 1 |
| Wu, LM | 1 |
| He, H | 1 |
| Chen, G | 1 |
| Kuang, Y | 1 |
| Lin, BY | 1 |
| Chen, XH | 1 |
| Zheng, SS | 1 |
| Sun, X | 1 |
| Liu, J | 4 |
| Wang, G | 1 |
| Li, Y | 1 |
| Tian, L | 1 |
| Zheng, H | 1 |
| Jia, C | 1 |
| Yu, X | 3 |
| Wang, T | 1 |
| Huang, S | 1 |
| Zeng, P | 1 |
| Zhang, J | 1 |
| Ji, X | 1 |
| Dong, Z | 1 |
| Lu, J | 2 |
| Zhao, Y | 1 |
| Li, R | 1 |
| Li, C | 1 |
| Chen, Y | 2 |
| Zhang, S | 1 |
| Du, T | 1 |
| Li, M | 2 |
| Lu, H | 1 |
| Lin, X | 1 |
| Zheng, R | 1 |
| Ren, P | 1 |
| Chen, Q | 1 |
| Yang, T | 1 |
| Chen, C | 1 |
| Mao, Y | 1 |
| Alegría-Díaz, A | 1 |
| Valdez-Ortiz, R | 1 |
| Murguía-Romero, M | 1 |
| Jiménez-Flores, R | 1 |
| Villalobos-Molina, R | 1 |
| Mummidi, S | 1 |
| Duggirala, R | 1 |
| López-Alvarenga, JC | 1 |
| Pérez-Navarro, M | 1 |
| Kuwabara, M | 1 |
| Borghi, C | 1 |
| Cicero, AFG | 1 |
| Hisatome, I | 1 |
| Niwa, K | 1 |
| Ohno, M | 1 |
| Johnson, RJ | 2 |
| Lanaspa, MA | 1 |
| Hou, YL | 1 |
| Yang, XL | 1 |
| Wang, CX | 1 |
| Zhi, LX | 1 |
| Yang, MJ | 1 |
| You, CG | 1 |
| Lai, YJ | 1 |
| Hsu, CY | 1 |
| Wu, J | 1 |
| Zhang, YP | 1 |
| Qu, Y | 1 |
| Jie, LG | 1 |
| Deng, JX | 1 |
| Yu, QH | 1 |
| Katsiki, N | 1 |
| Athyros, VG | 2 |
| Karagiannis, A | 2 |
| Mikhailidis, DP | 2 |
| Sun, K | 1 |
| Su, T | 1 |
| Xu, B | 1 |
| Xu, M | 1 |
| Bi, Y | 1 |
| Ning, G | 1 |
| Lin, Z | 1 |
| Zhang, B | 1 |
| Liu, X | 1 |
| Jin, R | 1 |
| Zhu, W | 1 |
| Barbieri, L | 1 |
| Verdoia, M | 1 |
| Schaffer, A | 1 |
| Cassetti, E | 1 |
| Marino, P | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Babio, N | 1 |
| Martínez-González, MA | 1 |
| Estruch, R | 1 |
| Wärnberg, J | 1 |
| Recondo, J | 1 |
| Ortega-Calvo, M | 1 |
| Serra-Majem, L | 1 |
| Corella, D | 1 |
| Fitó, M | 1 |
| Ros, E | 1 |
| Becerra-Tomás, N | 1 |
| Basora, J | 1 |
| Salas-Salvadó, J | 1 |
| Chen, S | 1 |
| Guo, X | 2 |
| Zhang, X | 1 |
| Yu, S | 2 |
| Yang, H | 2 |
| Jiang, M | 1 |
| Sun, G | 1 |
| Sun, Y | 2 |
| Zheng, L | 1 |
| Dornas, WC | 1 |
| de Lima, WG | 1 |
| Pedrosa, ML | 1 |
| Silva, ME | 1 |
| Ai, Z | 1 |
| Xu, R | 1 |
| Liu, W | 1 |
| Zhou, Q | 1 |
| Li, B | 1 |
| Huang, F | 1 |
| Yang, Q | 1 |
| Liang, S | 1 |
| Hu, Y | 1 |
| Liu, C | 1 |
| Qi, J | 1 |
| Li, G | 1 |
| Anagnostis, P | 1 |
| Tziomalos, K | 1 |
| Hauenschild, A | 1 |
| Bretzel, RG | 1 |
| Schnell-Kretschmer, H | 1 |
| Kloer, HU | 1 |
| Hardt, PD | 1 |
| Ewald, N | 1 |
| Wiernsperger, N | 1 |
| Geloen, A | 1 |
| Rapin, JR | 1 |
| Rodrigues, SL | 1 |
| Baldo, MP | 1 |
| Capingana, P | 1 |
| Magalhães, P | 1 |
| Dantas, EM | 1 |
| Molina, Mdel C | 1 |
| Salaroli, LB | 1 |
| Morelato, RL | 1 |
| Mill, JG | 1 |
| Gonçalves, JP | 1 |
| Oliveira, A | 1 |
| Severo, M | 1 |
| Santos, AC | 1 |
| Lopes, C | 1 |
| Kawada, T | 1 |
| Miglio, C | 1 |
| Peluso, I | 1 |
| Raguzzini, A | 1 |
| Villaño, DV | 1 |
| Cesqui, E | 1 |
| Catasta, G | 1 |
| Toti, E | 1 |
| Serafini, M | 1 |
| Chiu, CC | 1 |
| Chen, CH | 1 |
| Huang, MC | 1 |
| Chen, PY | 1 |
| Tsai, CJ | 1 |
| Lu, ML | 1 |
| Rozhkova, TA | 1 |
| Ameliushkina, VA | 1 |
| Iarovaia, EB | 1 |
| Kotkina, TI | 1 |
| Malusheva, PP | 1 |
| Titov, VN | 1 |
| He, S | 1 |
| Chen, XP | 1 |
| Jiang, LY | 1 |
| Peng, Y | 1 |
| He, JY | 1 |
| Gong, L | 1 |
| Wu, K | 1 |
| Cui, KJ | 1 |
| Zhu, Y | 1 |
| Huang, DJ | 1 |
| Damasceno, DC | 1 |
| Volpato, GT | 1 |
| de Mattos Paranhos Calderon, I | 1 |
| Cunha Rudge, MV | 1 |
| FELDMAN, EB | 1 |
| WALLACE, SL | 1 |
| Nakanishi, N | 1 |
| Nishina, K | 1 |
| Okamoto, M | 1 |
| Yoshida, H | 1 |
| Matsuo, Y | 1 |
| Suzuki, K | 1 |
| Tatara, K | 1 |
| Balasubramanian, T | 1 |
| Cicero, AF | 2 |
| Derosa, G | 2 |
| Miconi, A | 2 |
| Laghi, L | 2 |
| Nascetti, S | 2 |
| Gaddi, A | 2 |
| Loria, P | 1 |
| Lonardo, A | 1 |
| Lombardini, S | 1 |
| Carulli, L | 1 |
| Verrone, A | 1 |
| Ganazzi, D | 1 |
| Rudilosso, A | 1 |
| D'Amico, R | 1 |
| Bertolotti, M | 1 |
| Carulli, N | 1 |
| Zhao, LJ | 1 |
| Zhao, D | 1 |
| Wang, W | 1 |
| Wu, GX | 1 |
| Qin, LP | 1 |
| Liu, S | 1 |
| Wang, WH | 1 |
| Zeng, ZC | 1 |
| Nan, H | 1 |
| Qiao, Q | 1 |
| Dong, Y | 1 |
| Gao, W | 1 |
| Tang, B | 1 |
| Qian, R | 1 |
| Tuomilehto, J | 1 |
| Reungjui, S | 1 |
| Roncal, CA | 1 |
| Mu, W | 1 |
| Srinivas, TR | 1 |
| Sirivongs, D | 1 |
| Nakagawa, T | 1 |
| Akande, AA | 1 |
| Jimoh, AK | 1 |
| Akinyinka, OA | 1 |
| Olarinoye, GO | 1 |
| Omura, Y | 1 |
| Lu, DP | 1 |
| Shimotsura, Y | 1 |
| Ohki, M | 1 |
| Duvvi, H | 1 |
| Ebrahimpour, P | 1 |
| Fakhrzadeh, H | 1 |
| Heshmat, R | 1 |
| Bandarian, F | 1 |
| Larijani, B | 1 |
| Tinahones, FJ | 1 |
| Collantes, E | 2 |
| C-Soriguer, FJ | 2 |
| González-Ruiz, A | 1 |
| Pineda, M | 1 |
| Añón, J | 1 |
| Sánchez Guijo, P | 2 |
| Schmidt, MI | 1 |
| Duncan, BB | 1 |
| Watson, RL | 1 |
| Sharrett, AR | 1 |
| Brancati, FL | 1 |
| Heiss, G | 1 |
| Drabo, PY | 1 |
| Guira, O | 1 |
| Ouandaogo, BJ | 1 |
| Kabore, J | 1 |
| Kunes, J | 1 |
| Dobesová, Z | 1 |
| Zicha, J | 1 |
| Nakamura, H | 1 |
| Tinahones, JF | 1 |
| Pérez-Lindón, G | 1 |
| Pareja, A | 1 |
| Sánchez-Guijo, P | 1 |
| Paragh, G | 1 |
| Balogh, Z | 1 |
| Boda, J | 1 |
| Kovács, P | 1 |
| Kárpáti, L | 1 |
| Szabó, J | 1 |
| Leövey, A | 1 |
| Zhioua, R | 1 |
| Sebaï, L | 1 |
| Kriaa, L | 1 |
| el Euch, M | 1 |
| Mabrouk, S | 1 |
| Ouertani, A | 1 |
| Leyva, F | 1 |
| Wingrove, CS | 1 |
| Godsland, IF | 1 |
| Stevenson, JC | 1 |
| Adachi, H | 1 |
| Jacobs, DR | 1 |
| Hashimoto, R | 1 |
| Tsuruta, M | 1 |
| Imaizumi, T | 1 |
| Bonora, E | 1 |
| Kiechl, S | 1 |
| Willeit, J | 1 |
| Oberhollenzer, F | 1 |
| Egger, G | 1 |
| Targher, G | 1 |
| Alberiche, M | 1 |
| Bonadonna, RC | 1 |
| Muggeo, M | 1 |
| Luyckx, FH | 1 |
| Scheen, AJ | 1 |
| Desaive, C | 1 |
| Dewe, W | 1 |
| Gielen, JE | 1 |
| Lefebvre, PJ | 1 |
| Emmerson, B | 1 |
| Syrjänen, J | 1 |
| Mustonen, J | 1 |
| Pasternack, A | 1 |
| Idzior-Walus, B | 1 |
| Sieradzki, J | 1 |
| Rostworowski, W | 1 |
| Zdzienicka, A | 1 |
| Kawalec, E | 1 |
| Wójcik, J | 1 |
| Zarnecki, A | 1 |
| Blane, G | 1 |
| Treviño-Becerra, A | 1 |
| Pak, CY | 1 |
| Sakhaee, K | 1 |
| Peterson, RD | 1 |
| Poindexter, JR | 1 |
| Frawley, WH | 1 |
| Collantes Estevez, E | 1 |
| Pineda Priego, M | 1 |
| Añon Barbudo, J | 1 |
| Matsubara, K | 1 |
| Matsuzawa, Y | 1 |
| Jiao, S | 1 |
| Takama, T | 1 |
| Kubo, M | 1 |
| Tarui, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy[NCT02314533] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals[NCT01419535] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2011-11-29 | Completed | ||
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Omentectomy for Treatment of Diabetes Mellitus Type 2[NCT00270439] | Phase 1 | 10 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00884819] | 4 participants (Actual) | Interventional | 2008-12-31 | Terminated (stopped due to Poor recruitment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The adipose tissue insulin resistance index (Adipo-IR), a surrogate measure for fasting adipose-tissue insulin resistance, was calculated as the product of fasting insulin and fasting free fatty acids (FFA) (NCT01419535)
Timeframe: 9 days
| Intervention | mmol/l·μU/l (Mean) |
|---|---|
| Post-mifepristone | 49.9 |
| Post-placebo | 65.5 |
The Adipo-SI was calculated as ratio of the slope of the linear decrease in natural log transformed FFA [Ln (FFA) slope] during the first 90 minutes of the FSIVGTT and the area under the curve (AUC) of insulin during that 90-minute period (AUC Insulin 0-90 min). (NCT01419535)
Timeframe: 9 days
| Intervention | ln(mmol /uU/mL*min)*10^8 (Mean) |
|---|---|
| Post-mifepristone | 61.7 |
| Post-placebo | 42.8 |
Fasting insulin after study agent administration compared to baseline (NCT01419535)
Timeframe: 9 days
| Intervention | pmol/L (Mean) |
|---|---|
| Post-mifepristone | 95.6 |
| Post-placebo | 142.8 |
fasting plasma glucose after study agent compared to baseline (NCT01419535)
Timeframe: Nine days
| Intervention | mg/dL (Mean) |
|---|---|
| Post-mifepristone | 100.4 |
| Post-placebo | 107.8 |
insulin sensitivity index based on the effect of insulin on glucose during frequently sampled intravenous glucose tolerance test (FSIVGTT) (NCT01419535)
Timeframe: Nine days
| Intervention | min-1·μU·ml-1 (Mean) |
|---|---|
| Post-mifepristone | 1.49 |
| Post-placebo | 1.41 |
HOMA-IR is an index of insulin resistance, measured as glucose in mmol/L x insulin in mIU/mL)/22.5. HOMA-IR > 2.5 indicates insulin resistance. (NCT01419535)
Timeframe: 9 days
| Intervention | units on a scale (Mean) |
|---|---|
| Post-mifepristone | 3.58 |
| Post-placebo | 5.78 |
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
7 reviews available for uric acid and Hypertriglyceridemia
| Article | Year |
|---|---|
Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis.
Topics: Fenofibrate; Humans; Hypertriglyceridemia; Treatment Outcome; Uric Acid | 2021 |
Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview.
Topics: Endothelium, Vascular; Female; Humans; Hypertriglyceridemia; Lipoproteins, HDL; Lipoproteins, LDL; L | 2014 |
Health implications of high-fructose intake and current research.
Topics: Animals; Diet; Dietary Sucrose; Fructose; Humans; Hypertension; Hypertriglyceridemia; Insulin; Insul | 2015 |
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipokines; Birth Weight; Blood Coagulation Disorders; | 2009 |
Fructose and cardiometabolic disorders: the controversy will, and must, continue.
Topics: Diet; Fructose; Humans; Hypertriglyceridemia; Liver; Metabolic Syndrome; Risk Factors; Sweetening Ag | 2010 |
[Association of hyperuricemia with hyperlipidemia and obesity].
Topics: Fatty Acids, Nonesterified; Female; Humans; Hypertriglyceridemia; Lipoprotein Lipase; Male; Obesity; | 1996 |
The glycolytic pathway to coronary heart disease: a hypothesis.
Topics: Animals; Coronary Disease; Glyceraldehyde-3-Phosphate Dehydrogenases; Glycolysis; Humans; Hypertrigl | 1998 |
5 trials available for uric acid and Hypertriglyceridemia
| Article | Year |
|---|---|
Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fenofibrate; Gl | 2020 |
Antioxidant and inflammatory response following high-fat meal consumption in overweight subjects.
Topics: Adult; Antioxidants; Body Mass Index; Diet, High-Fat; Female; Humans; Hypercholesterolemia; Hypertri | 2013 |
Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates.
Topics: Adult; Blood Pressure; Cholesterol; Coenzymes; Creatinine; Drug Resistance; Drug Therapy, Combinatio | 2005 |
Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients.
Topics: Adult; Diet; Energy Intake; Humans; Hypertriglyceridemia; Kidney; Lipoproteins, VLDL; Male; Middle A | 1997 |
Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Glucose; Blood | 2000 |
57 other studies available for uric acid and Hypertriglyceridemia
| Article | Year |
|---|---|
A Clinical Profile of Patients with Hyperuricemia and the Relationship between Hyperuricemia and Metabolic Syndrome: A Cross-sectional Study at a Tertiary Hospital in the Indian Population.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Hypertriglyceridemia; Hyperuricemi | 2022 |
Risk Factors for Hyperuricemia or Gout in Men and Women: The Circulatory Risk in Communities Study (CIRCS).
Topics: Diabetes Mellitus; Female; Gout; Humans; Hypercholesterolemia; Hypertension; Hypertriglyceridemia; H | 2023 |
The association between serum uric acid and hypertriglyceridemia: evidence from the national health and nutrition examination survey (2007-2018).
Topics: Adult; Cross-Sectional Studies; Humans; Hyperlipidemias; Hypertriglyceridemia; Nutrition Surveys; Ri | 2023 |
An analysis of the associations of high-sensitivity C-reactive protein and uric acid with metabolic syndrome components in Korean adults by sex: a cross-sectional study using the Korea national health and nutrition examination survey 2016-2018.
Topics: Adult; C-Reactive Protein; Cross-Sectional Studies; Female; Humans; Hypertension; Hypertriglyceridem | 2023 |
Sex-specific association of hyperuricemia with cardiometabolic abnormalities in a military cohort: The CHIEF study.
Topics: Adolescent; Adult; Cross-Sectional Studies; Female; Humans; Hypertension; Hypertriglyceridemia; Hype | 2020 |
Associations between obesity and metabolic health with nonalcoholic fatty liver disease in elderly Chinese.
Topics: Aged; Blood Glucose; Blood Pressure; Body Mass Index; China; Cholesterol; Cross-Sectional Studies; F | 2020 |
Serum uric acid and risk of incident hypercholesterolaemia and hypertriglyceridaemia in middle-aged and older Chinese: a 4-year prospective cohort study.
Topics: Aged; Biomarkers; China; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Hypercholestero | 2020 |
Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis.
Topics: Age Factors; Causality; Cholesterol; Dyslipidemias; Genome-Wide Association Study; Gout; Humans; Hyp | 2021 |
Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia.
Topics: Adult; Aged; China; Cohort Studies; Cross-Sectional Studies; Female; Humans; Hypertriglyceridemia; H | 2017 |
Serum Uric Acid Levels and Risk of Incident Hypertriglyceridemia: A Longitudinal Population-based Epidemiological Study.
Topics: Adult; China; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Female; Glomerular F | 2017 |
Clinical Significance of Serum Uric Acid Levels in Mexican Young Adults.
Topics: Adolescent; Adult; Cholesterol, LDL; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hu | 2018 |
Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cholesterol, LDL; Cohort Studies; Female; Humans; Hypert | 2018 |
Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents.
Topics: Adult; Aged; Female; Humans; Hypertriglyceridemia; Hyperuricemia; Lipid Metabolism; Male; Middle Age | 2019 |
Is serum uric acid a predictive factor for stroke in men with hypertriglyceridemia?
Topics: Aged; Biomarkers; Humans; Hypertriglyceridemia; Hyperuricemia; Male; Middle Aged; Predictive Value o | 2019 |
Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
Topics: Adult; Allopurinol; Benzbromarone; Biomarkers; Cholesterol; Febuxostat; Female; Gout; Gout Suppressa | 2019 |
Serum potassium level is associated with metabolic syndrome: a population-based study.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; China; Cholesterol, HDL; Cholesterol, LDL; Cross | 2014 |
Effects of chicory inulin on serum metabolites of uric acid, lipids, glucose, and abdominal fat deposition in quails induced by purine-rich diets.
Topics: Abdominal Fat; Acetyl-CoA Carboxylase; Animals; Blood Glucose; Cichorium intybus; Diet; Disease Mode | 2014 |
Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Choleste | 2015 |
Associations between serum uric acid concentrations and metabolic syndrome and its components in the PREDIMED study.
Topics: Aged; Aged, 80 and over; Asian People; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; C | 2015 |
Association between elevated serum alanine aminotransferase and cardiometabolic risk factors in rural Chinese population: a cross-sectional study.
Topics: Adult; Age Factors; Aged; Alanine Transaminase; Blood Pressure; Body Mass Index; Cardiovascular Dise | 2015 |
Hyperuricemia is independently associated with left ventricular hypertrophy in post-menopausal women but not in pre-menopausal women in rural Northeast China.
Topics: Adult; Age Factors; Aged; Body Mass Index; China; Diabetes Mellitus; Dyslipidemias; Female; Humans; | 2015 |
Clinicopathologic features of IgA nephropathy patients with different levels of proteinuria.
Topics: Adult; Atrophy; Biopsy; Female; Fibrosis; Glomerular Filtration Rate; Glomerulonephritis, IGA; Glome | 2016 |
Low insulin-like growth factor 1 is associated with low high-density lipoprotein cholesterol and metabolic syndrome in Chinese nondiabetic obese children and adolescents: a cross-sectional study.
Topics: Adolescent; Alanine Transaminase; Blood Glucose; Body Mass Index; Case-Control Studies; Child; Chole | 2016 |
Successful treatment of severe hypertriglyceridemia with a formula diet rich in omega-3 fatty acids and medium-chain triglycerides.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Mass Index; Diet; Dietary Carbohydrates; Dietary Fats; | 2010 |
Gender distribution of serum uric acid and cardiovascular risk factors: population based study.
Topics: Adult; Biomarkers; Body Mass Index; Brazil; Epidemiologic Methods; Female; Humans; Hypertension; Hyp | 2012 |
Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Confounding Factors, Epidemiologic; Cros | 2012 |
Predictors of the development of metabolic syndrome in male workers: a 3-year follow-up study.
Topics: Adult; Age Factors; Alcohol Drinking; Cholesterol, HDL; Confidence Intervals; Exercise; Follow-Up St | 2012 |
The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Cholesterol, HDL; Cross-Sectional Studies; Female; Humans; Hypertension; Hypertriglyceridemia | 2012 |
[The hyperuricosuria in patients with high content of triglycerides: the combination of genetic and environmental factors and tactics of treatment].
Topics: Adolescent; Adult; Aged; Environment; Fructose; Humans; Hypertension; Hypertriglyceridemia; Lipoprot | 2012 |
[Association between serum uric acid and prevalence of hypertriglyceridemia in middle and old aged people].
Topics: Aged; Female; Humans; Hypertriglyceridemia; Male; Middle Aged; Prevalence; Uric Acid | 2010 |
Oxidative stress and diabetes in pregnant rats.
Topics: Animals; Antioxidants; Congenital Abnormalities; Diabetes Mellitus, Experimental; Female; Gestationa | 2002 |
HYPERTRIGLYCERIDEMIA IN GOUT.
Topics: Arteriosclerosis; Black People; Blood Chemical Analysis; Cholesterol; Genetics, Medical; Geriatrics; | 1964 |
Clustering of components of the metabolic syndrome and risk for development of type 2 diabetes in Japanese male office workers.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Cholesterol, LDL; Cluster Analysis; Dia | 2004 |
Uric acid or 1-methyl uric acid in the urinary bladder increases serum glucose, insulin, true triglyceride, and total cholesterol levels in Wistar rats.
Topics: Administration, Intravesical; Animals; Blood Glucose; Cholesterol; Female; Hypercholesterolemia; Hyp | 2003 |
Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10?
Topics: Adult; Blood Pressure; Cholesterol; Coenzymes; Creatinine; Diet; Drug Resistance; Fatty Acids, Omega | 2005 |
Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors.
Topics: Age Factors; Apolipoproteins B; Biopsy; Cholecystolithiasis; Cholesterol; Fatty Liver; Female; Gallb | 2005 |
[Association between serum uric acid and triglyceride in a Chinese community].
Topics: Adult; China; Cross-Sectional Studies; Female; Humans; Hypertriglyceridemia; Logistic Models; Male; | 2005 |
The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China.
Topics: Adult; Aged; Alcohol Drinking; China; Cross-Sectional Studies; Female; Gout; Humans; Hypercholestero | 2006 |
Thiazide diuretics exacerbate fructose-induced metabolic syndrome.
Topics: Allopurinol; Animals; Blood Pressure; Body Weight; Diuretics; Fructose; Gout Suppressants; Hydrochlo | 2007 |
Serum uric acid level as an independent component of the metabolic syndrome in type 2 diabetic blacks.
Topics: Adult; Aged; Black People; Diabetes Mellitus, Type 2; Epidemiologic Studies; Female; Humans; Hypertr | 2007 |
Anatomical relationship between traditional acupuncture point ST 36 and Omura's ST 36 (True ST 36) with their therapeutic effects: 1) inhibition of cancer cell division by markedly lowering cancer cell telomere while increasing normal cell telomere, 2) im
Topics: Acupuncture; Acupuncture Points; Blood Cell Count; Blood Glucose; C-Reactive Protein; Cardiovascular | 2007 |
Serum uric acid levels and risk of metabolic syndrome in healthy adults.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Female; Humans; Hypertension; Hypertriglyceridemia; Hype | 2008 |
Increased VLDL levels and diminished renal excretion of uric acid in hyperuricaemic-hypertriglyceridaemic patients.
Topics: Adult; Apolipoproteins B; Cholesterol, HDL; Humans; Hypertriglyceridemia; Lipoproteins, VLDL; Male; | 1995 |
A metabolic syndrome in whites and African-Americans. The Atherosclerosis Risk in Communities baseline study.
Topics: Arteriosclerosis; Black People; Cholesterol, HDL; Cluster Analysis; Diabetes Mellitus; Ethnicity; Fe | 1996 |
[Arterial hypertension and diabetes in Ouagadougou (Burkina Faso)].
Topics: Adult; Aged; Burkina Faso; Diabetes Complications; Diabetic Angiopathies; Female; Humans; Hyperchole | 1996 |
High blood pressure of hypertriglyceridaemic rats is related to metabolic disturbances.
Topics: Animals; Blood Pressure; Crosses, Genetic; Female; Hypertension; Hypertriglyceridemia; Kidney; Lipid | 1995 |
Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia.
Topics: Apolipoprotein A-I; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; | 1997 |
[Risk factors and etiology of retinal vein occlusion].
Topics: Adult; Age Factors; Aged; Arteriosclerosis; Behcet Syndrome; Coronary Disease; Diabetes Complication | 1995 |
Clustering of cardiovascular risk factors in hyperinsulinemia in Japanese without diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Hyperinsulinism; Hypertensio | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity.
Topics: Adult; Belgium; Body Mass Index; Body Weight; Cholesterol; Cholesterol, HDL; Cohort Studies; Comorbi | 1998 |
Hyperlipidaemia in hyperuricaemia and gout.
Topics: Gout; Humans; Hyperinsulinism; Hypertriglyceridemia; Insulin Resistance; Uric Acid | 1998 |
Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy.
Topics: Adolescent; Adult; Aged; Child; Female; Glomerulonephritis, IGA; Humans; Hypercholesterolemia; Hyper | 2000 |
Hypertriglyceridaemia and hyperuricaemia in IgA nephropathy.
Topics: Glomerulonephritis, IGA; Humans; Hypertriglyceridemia; Middle Aged; Uric Acid | 2001 |
Biochemical profile of idiopathic uric acid nephrolithiasis.
Topics: Adult; Female; Gout; Humans; Hydrogen-Ion Concentration; Hypertriglyceridemia; Kidney Calculi; Male; | 2001 |
Hyperuricemia-hyperlipemia association in the absence of obesity and alcohol abuse.
Topics: Adult; Alcohol Drinking; Cholesterol; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertension; H | 1990 |
Relationship between hypertriglyceridemia and uric acid production in primary gout.
Topics: Alcohol Drinking; Cholesterol; Cholesterol, HDL; Gout; Humans; Hypertriglyceridemia; Male; Reference | 1989 |